NK cells with bispecific antibody yield high response rates in patients with lymphoma: Clinical trial
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...
Mirage News3h
NK Cells, Bispecific Antibody Boost Lymphoma Response
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or ...
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of ...
Healio8h
Experimental therapy for brain cancer gives ‘hope’; will be investigated in upcoming trial
An award-winning pathologist who devoted his life to melanoma research became the first person to receive a novel ...
Mirage News8h
Bispecific Antibody Boosts NK Cell Response in Lymphoma
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...
Technology Networks17h
Novel Cell Therapy Yields Promising Response Rates in Lymphoma Patients
A novel cell therapy approach using natural killer cells pre-complexed with a bispecific antibody, was safe and generated ...